SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Immix Biopharma Is Maintained at Buy by Needham

Ratings actions from Benzinga: GMT) Immix Biopharma Price Target Raised to $30.00/Share From $21.00 by NeedhamRatings actions from Benzinga

IMMX

Related stories